Kenmore Mercy Hospital | |
2950 Elmwood Avenue, Kenmore, New York 14217 | |
(716) 447-6100 | |
Name | Kenmore Mercy Hospital |
---|---|
Type | Acute Care Hospital |
Location | 2950 Elmwood Avenue, Kenmore, New York |
Ownership | Voluntary non-profit - Church |
Emergency Services | Yes |
Medicare ID (CCN) | 330102 |
NPI Number | 1093192734 |
Organization Name | KENMORE MERCY HOSPITAL |
Address | 2950 Elmwood Ave, Kenmore, NY 14217 |
Hospital Type | General Acute Care Hospital |
Phone Number | 716-447-6002 |
News Archive
A $10.8 million grant from the National Institutes of Health will enable an interdisciplinary team of researchers at the University of Arkansas and University of Arkansas for Medical Sciences to address the role of cell and tissue metabolism in rare and common diseases such as cancer, diabetes, obesity and mitochondrial disorders.
QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.
Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.
Australian scientists have made a breakthrough which could help in the fight against cancer. The team from Peter MacCallum Cancer Centre in Melbourne has found a link between non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and the ability of tumours to spread in the body. They say that doctors have been aware of the benefits of NSAIDs for many years, but did not fully understand the biological processes involved.
› Verified 6 days ago
NPI Number | 1619424884 |
Organization Name | BUFFALO NIAGARA HOSPITALIST LLC |
Address | 2950 Elmwood Ave, Kenmore, NY 14217 |
Hospital Type | General Acute Care Hospital |
Phone Number | 716-447-6100 |
News Archive
A $10.8 million grant from the National Institutes of Health will enable an interdisciplinary team of researchers at the University of Arkansas and University of Arkansas for Medical Sciences to address the role of cell and tissue metabolism in rare and common diseases such as cancer, diabetes, obesity and mitochondrial disorders.
QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.
Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.
Australian scientists have made a breakthrough which could help in the fight against cancer. The team from Peter MacCallum Cancer Centre in Melbourne has found a link between non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and the ability of tumours to spread in the body. They say that doctors have been aware of the benefits of NSAIDs for many years, but did not fully understand the biological processes involved.
› Verified 6 days ago
NPI Number | 1770598104 |
Organization Name | KENMORE MERCY HOSPITAL |
Address | 2950 Elmwood Ave, Kenmore, NY 14217 |
Hospital Type | General Acute Care Hospital |
Phone Number | 716-447-6100 |
News Archive
A $10.8 million grant from the National Institutes of Health will enable an interdisciplinary team of researchers at the University of Arkansas and University of Arkansas for Medical Sciences to address the role of cell and tissue metabolism in rare and common diseases such as cancer, diabetes, obesity and mitochondrial disorders.
QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.
Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.
Australian scientists have made a breakthrough which could help in the fight against cancer. The team from Peter MacCallum Cancer Centre in Melbourne has found a link between non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and the ability of tumours to spread in the body. They say that doctors have been aware of the benefits of NSAIDs for many years, but did not fully understand the biological processes involved.
› Verified 6 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | No |
News Archive
A $10.8 million grant from the National Institutes of Health will enable an interdisciplinary team of researchers at the University of Arkansas and University of Arkansas for Medical Sciences to address the role of cell and tissue metabolism in rare and common diseases such as cancer, diabetes, obesity and mitochondrial disorders.
QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.
Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.
Australian scientists have made a breakthrough which could help in the fight against cancer. The team from Peter MacCallum Cancer Centre in Melbourne has found a link between non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and the ability of tumours to spread in the body. They say that doctors have been aware of the benefits of NSAIDs for many years, but did not fully understand the biological processes involved.
› Verified 6 days ago
Kenmore Mercy Hospital Acute Care Hospital Location: 2950 Elmwood Avenue, Kenmore, New York 14217 Phone: (716) 447-6100 |